Abstract 2860
Background
Although, previous studies reported that metabolic response (MR) assessed by post-CRT 18FDG-PET was associated with survival outcomes in ESCC treated with dCRT, there are few data on the prognostic value of each metabolic response category after induction chemotherapy prior to dCRT and after completion of dCRT.
Methods
In this retrospective study, we evaluated prognostic value of MR after completion of induction chemotherapy and after completion of dCRT in 382 localized ESCC pts receiving induction chemotherapy followed by dCRT from January 2012 to February 2018 at Asan Medical Center in Korea. MR was assessed by EORTC criteria.
Results
MR after induction chemotherapy was significantly associated with progression-free survival (PFS) and overall survival (OS). MR after dCRT was also significantly associated with PFS and OS. MR after either induction chemotherapy or dCRT remained significant after adjusting for other prognostic factors such as clinical TNM stage, sex, and ECOG performance status. Whereas pts achieving mCR/mPR or mPD after either induction chemotherapy or dCRT had good prognosis or poor prognosis, respectively, the prognostic value of mSD was different between post-induction chemotherapy and post-dCRT; it was similar to that of mPR after induction chemotherapy, but it was similar to that of mPD after dCRT. Poorer MR to induction chemotherapy could predict the lack of MR after dCRT; the proportion of mSD/mPD after dCRT was 7.7% in pts with post-induction mCR vs. 16.0% in pts with vs. 40.0% in pts with post-induction mSD vs. 100% in pts with post-induction mPD (p = 0.001).Table:
762P
Post induction chemotherapy | Post-dCRT | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
metabolic response | N | HR for PFS (95% CI) | P-value | HR for OS (95% CI) | P-value | N | HR for PFS (95% CI) | P-value | HR for OS (95% CI) | P-value |
mCR | 13 | 1 | 1 | 150 | 1 | 1 | ||||
mPR | 106 | 3.348 (1.221-9.181) | 0.019 | 2.498 (1.008 - 6.192) | 0.048 | 164 | 2.182 (1.646-2.892) | 0.000 | 2.224 (1.694-2.919) | 0.000 |
mSD | 10 | 6.008 (1.179-20.150) | 0.004 | 3.640 (1.186-11.171) | 0.024 | 7 | 11.251 (5.088-24.878) | 0.000 | 9.659 (4.393-21.236) | 0.000 |
mPD | 2 | 59.209 (9.430-371.767) | 0.000 | 14.495 (2.676-78.503) | 0.002 | 39 | 21.768 (14.020-33.797) | 0.000 | 10.592 (7.016-15.989) | 0.000 |
diffuse esophagitis | 3 | 1.729 (0.193-15.482) | 0.624 | 1.103 (0.129-9.453) | 0.929 | 22 | 1.169 (0.651-2.098) | 0.601 | 1.482 (0.856-2.566) | 0.160 |
Total | 134 | 0.000 | 0.027 | 382 | 0.000 | 0.000 |
Conclusions
MR after induction chemotherapy and after CRT had independent prognostic value with different prognostication between each other in ESCC pts receiving induction chemotherapy followed by dCRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1571 - Thyroid Lobectomy versus Total Thyroidectomy among Early-Stage Papillary Thyroid Carcinoma Patient
Presenter: Sara Ahmed
Session: Poster Display session 2
Resources:
Abstract
5051 - Classification of thyroid nodule using DNA methylation profiling on tissue and circulating tumor DNA
Presenter: Shubin Hong
Session: Poster Display session 2
Resources:
Abstract
4155 - Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Refractory and Progressive Advanced Thyroid Carcinoma. A Phase II Multicohort Trial (DUTHY / GETNE T1812)
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract